Literature DB >> 31430503

Lack of evidence for long term carriers of African swine fever virus - a systematic review.

Karl Ståhl1, Susanna Sternberg-Lewerin2, Sandra Blome3, Arvo Viltrop4, Mary-Louise Penrith5, Erika Chenais6.   

Abstract

African swine fever (ASF) was first described in 1921 as a highly fatal and contagious disease which caused severe outbreaks among settlers' pigs in British East Africa. Since then the disease has expanded its geographical distribution and is currently present in large parts of Africa, Europe and Asia and considered a global threat. Although ASF is typically associated with very high case fatality rates, a certain proportion of infected animals will recover from the infection and survive. Early on it was speculated that such survivors may act as carriers of the virus, and the importance of such carries for disease persistence and spread has since then almost become an established truth. However, the scientific basis for such a role of carriers may be questioned. With this in mind, the objective of this study was to review the available literature in a systematic way and to evaluate the available scientific evidence. The selection of publications for the review was based on a database search, followed by a stepwise screening process in order to exclude duplicates and non-relevant publications based on pre-defined exclusion criteria. By this process the number of publications finally included was reduced from the 3664 hits identified in the initial database search to 39 publications, from which data was then extracted and analysed. Based on this it was clear that a definition of an ASF virus carrier is lacking, and that in general any survivor or seropositive animal has been referred to as carrier. It was also clear that evidence of any significant role of such a carrier is absent. Two types of "survivors" could be defined: 1) pigs that do not die but develop a persistent infection, characterised by periodic viraemia and often but not always accompanied by some signs of subacute to chronic disease, and 2) pigs which clear the infection independently of virulence of the virus, and which are not persistently infected and will not present with prolonged virus excretion. There is no evidence that suggests that any of these categories of survivors can be considered as "healthy" carriers, i.e. pigs that show no sign of disease but can transmit the virus to in-contact pigs. However, localized virus persistence in lymphoid tissues may occur to some extent in any of the categories of survivors, which in theory may cause infection after oral uptake. To what extent this is relevant in reality, however, can be questioned given the virus dose generally needed for oral infection.
Copyright © 2019 The Authors. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  ASF; carrier; chronic; persistent; reservoir; survivor

Mesh:

Year:  2019        PMID: 31430503     DOI: 10.1016/j.virusres.2019.197725

Source DB:  PubMed          Journal:  Virus Res        ISSN: 0168-1702            Impact factor:   3.303


  17 in total

1.  ASF Exit Strategy: Providing cumulative evidence of the absence of African swine fever virus circulation in wild boar populations using standard surveillance measures.

Authors:  Søren Saxmose Nielsen; Julio Alvarez; Dominique Joseph Bicout; Paolo Calistri; Klaus Depner; Julian Ashley Drewe; Bruno Garin-Bastuji; Jose Luis Gonzales Rojas; Christian Gortazar Schmidt; Mette Herskin; Virginie Michel; Miguel Ángel Miranda Chueca; Paolo Pasquali; Helen Clare Roberts; Liisa Helena Sihvonen; Hans Spoolder; Karl Stahl; Antonio Velarde; Christoph Winckler; José Cortiňas Abrahantes; Sofie Dhollander; Corina Ivanciu; Alexandra Papanikolaou; Yves Van der Stede; Sandra Blome; Vittorio Guberti; Federica Loi; Simon More; Edvins Olsevskis; Hans Hermann Thulke; Arvo Viltrop
Journal:  EFSA J       Date:  2021-03-03

2.  Social structure defines spatial transmission of African swine fever in wild boar.

Authors:  Kim M Pepin; Andrew Golnar; Tomasz Podgórski
Journal:  J R Soc Interface       Date:  2021-01-20       Impact factor: 4.118

3.  Possibility of long-term survival of African swine fever virus in natural conditions.

Authors:  Hranush Arzumanyan; Sona Hakobyan; Hranush Avagyan; Roza Izmailyan; Narek Nersisyan; Zaven Karalyan
Journal:  Vet World       Date:  2021-04-09

4.  A Long-Term Study of the Biological Properties of ASF Virus Isolates Originating from Various Regions of the Russian Federation in 2013-2018.

Authors:  Andrei Pershin; Ivan Shevchenko; Alexey Igolkin; Ivan Zhukov; Ali Mazloum; Elena Aronova; Natalia Vlasova; Alexander Shevtsov
Journal:  Vet Sci       Date:  2019-12-06

Review 5.  With or without a Vaccine-A Review of Complementary and Alternative Approaches to Managing African Swine Fever in Resource-Constrained Smallholder Settings.

Authors:  Mary-Louise Penrith; Armanda Bastos; Erika Chenais
Journal:  Vaccines (Basel)       Date:  2021-02-02

6.  Thoughts on African Swine Fever Vaccines.

Authors:  Daniel L Rock
Journal:  Viruses       Date:  2021-05-20       Impact factor: 5.048

7.  Evaluation of Lesions and Viral Antigen Distribution in Domestic Pigs Inoculated Intranasally with African Swine Fever Virus Ken05/Tk1 (Genotype X).

Authors:  Pedro J Sánchez-Cordón; Tobias Floyd; Daniel Hicks; Helen R Crooke; Stephen McCleary; Ronan R McCarthy; Rebecca Strong; Linda K Dixon; Aleksija Neimanis; Emil Wikström-Lassa; Dolores Gavier-Widén; Alejandro Núñez
Journal:  Pathogens       Date:  2021-06-18

8.  Evolution of the ASF Infection Stage in Wild Boar Within the EU (2014-2018).

Authors:  Marta Martínez-Avilés; Irene Iglesias; Ana De La Torre
Journal:  Front Vet Sci       Date:  2020-04-01

9.  Modelling the transmission and persistence of African swine fever in wild boar in contrasting European scenarios.

Authors:  Xander O'Neill; Andy White; Francisco Ruiz-Fons; Christian Gortázar
Journal:  Sci Rep       Date:  2020-04-03       Impact factor: 4.379

10.  Mathematical Approach to Estimating the Main Epidemiological Parameters of African Swine Fever in Wild Boar.

Authors:  Federica Loi; Stefano Cappai; Alberto Laddomada; Francesco Feliziani; Annalisa Oggiano; Giulia Franzoni; Sandro Rolesu; Vittorio Guberti
Journal:  Vaccines (Basel)       Date:  2020-09-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.